Fundraising Fox
/People
Sign in

Dean Slagel

Investor

Managing Director at Esperante Ventures

United Kingdom

Find your path to Dean

40 people in our graph can introduce you to Dean.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Amanda Wooding to introduce you to Dean

You →Amanda · together at Ferring Pharmaceuticals (1997–1999) →Dean

Ask Jamie Chen to introduce you to Dean

You →Jamie · 11 people · together at Ferring Pharmaceuticals →Dean

Sign up to find every way you can get introduced to Dean

  • Your email: the people you already email who know Dean
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Dean
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Dean Slagel is Managing Director at Marom Advisory Partners and was the founding Managing Director of Esperante Ventures, where he oversaw investments of EUR 500k–5m in mid-to-late stage therapeutics and commercial-stage diagnostics across North America, Europe and Israel. His track record includes 25+ portfolio investments, five exits and four public listings, among them the IPOs of Cara Therapeutics, Altimmune and Medicenna Therapeutics, and he has served as investor or non-executive director on nine biotech boards. Earlier, he held business development roles at Ferring Pharmaceuticals in Paris and Copenhagen and at Tillotts Pharma in Basel, covering licensing and international market development in regions including Mexico, Russia, Israel, Saudi Arabia and Canada.

Contact· self-published, not guessed

Experience

  1. Marom Advisory PartnersManaging Directorcurrent2026 — presentGreater London, England, United Kingdom
  2. Esperante VenturesManaging Director2004 — 2026London Area, United Kingdom
  3. Ferring PharmaceuticalsGlobal Business Development Director2001 — 2003Greater Paris Metropolitan Region
  4. Ferring PharmaceuticalsProject Director, International Business Development & Regional Management1995 — 2001Greater Paris Metropolitan Region
  5. Tillotts Pharma AGInternational Marketing Director1991 — 1995Basel, Basel, Switzerland

Skills & more

Exit StrategiesLife Science IndustryRegulatory AffairsMarketingProject ManagementCorporate Venture CapitalDeal ExecutionInitial Public Offerings (IPO)Biotechnology IndustryMergers & Acquisitions (M&A)Board GovernanceNon-Executive Director
+11 moreVenture CapitalLifesciencesStart-upsPharmaceuticsManagementBiotechnologyPharmaceutical IndustryCorporate DevelopmentStrategyDue DiligenceTechnology Transfer

Languages English · French · German

  • MBA

From Dean's professional profile.

Frequently asked questions

Who is Dean Slagel?
Dean Slagel is Managing Director at Marom Advisory Partners and was the founding Managing Director of Esperante Ventures, where he oversaw investments of EUR 500k–5m in mid-to-late stage therapeutics and commercial-stage diagnostics across North America, Europe and Israel. His track record includes 25+ portfolio investments, five exits and four public listings, among them the IPOs of Cara Therapeutics, Altimmune and Medicenna Therapeutics, and he has served as investor or non-executive director on nine biotech boards. Earlier, he held business development roles at Ferring Pharmaceuticals in Paris and Copenhagen and at Tillotts Pharma in Basel, covering licensing and international market development in regions including Mexico, Russia, Israel, Saudi Arabia and Canada.
Where does Dean Slagel work?
Dean Slagel is Managing Director at Esperante Ventures.
Where did Dean Slagel go to school?
Dean Slagel studied at École des Ponts Business School (Master of Business Administration); St Albans School.

Same school

Shared employers